Then, the FLINT trial (FXR Ligand Obeticholic Acid in NASH Treatment, NCT01265498) included NASH patients treated with OCA (25 mg/day) for 72 weeks [83]. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.